ABVC BioPharma (ABVC) AI Stock Analysis

• Market Cap: $52.98M
• Dividend Yield: N/A
• Average Volume (3M): 95.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.61
• Revenue Growth: 56.52%
• EPS Growth: 75.22%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 24,301,088
• 10 Day Avg. Volume: 116,541
• 30 Day Avg. Volume: 95,045
• PEG Ratio: 0.02
• Price to Book (P/B): 5.62
• Price to Sales (P/S): 13.52
• P/FCF Ratio: -3.81
• Enterprise Value/Market Cap: 0.19
• Enterprise Value/Revenue: 12.48
• Enterprise Value/Gross Profit: 12.48
• Enterprise Value/Ebitda: -2.48
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $2.00 ▼(-17.70% Downside)

The score is held down primarily by weak financial performance (heavy losses and ongoing cash burn) despite improved revenue and lower leverage. Technicals are mixed with slightly negative momentum, and valuation is constrained by a negative P/E and no dividend yield data.

Positive Factors

Revenue Growth

The significant revenue increase indicates strong business execution and potential for future growth, enhancing the company's market position.

Cost Reductions

Effective cost management and improved earnings per share reflect operational efficiency, supporting long-term profitability and sustainability.

Partnerships and Milestone Payments

Strong partnerships and milestone payments provide financial resources for growth without dilutive financing, enhancing strategic flexibility.

Negative Factors

High Leverage

High leverage limits financial flexibility and increases risk, potentially impacting the company's ability to invest in growth opportunities.

Negative Cash Flow

Negative cash flow indicates financial strain, limiting the company's ability to fund operations and growth internally, necessitating external financing.

Lack of Profitability

Persistent lack of profitability undermines financial stability and limits reinvestment capacity, posing a challenge to long-term viability.

ABVC BioPharma Business Overview & Revenue Model

Company Description

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

How the Company Makes Money

ABVC BioPharma, Inc. generates revenue primarily through the development and commercialization of its proprietary drug candidates and medical devices. The company's revenue model includes licensing agreements, partnerships with other pharmaceutical companies, and potentially direct sales of successfully developed therapeutics and devices. Significant partnerships and collaborations with research institutions and healthcare organizations play a crucial role in advancing ABVC's product pipeline and can lead to milestone payments, royalties, and other income streams as products progress through clinical trials and receive regulatory approval.

ABVC BioPharma Financial Statement Overview

Summary

ABVC BioPharma, Inc. demonstrates significant financial weaknesses across all verticals. The company is not profitable, highly leveraged, and struggles with cash flow generation. While there are minor improvements in revenue, the overall financial health remains concerning. Immediate strategic interventions are necessary to address profitability, leverage, and cash flow challenges.

Income Statement

The company has consistently generated negative net income over the years, indicating a lack of profitability. Revenue has fluctuated, with a significant decrease from 2022 to 2023, followed by a slight increase in 2024. Margins are weak with negative EBIT and EBITDA margins, reflecting operational inefficiency. Overall, the income statement shows poor financial performance with no clear trend of improvement.

Balance Sheet

The balance sheet reveals high leverage, with a debt-to-equity ratio suggesting significant reliance on debt financing. Stockholders' equity has decreased markedly from 2023 to 2024, and the equity ratio is low, indicating limited equity cushion. While the company has managed to maintain its total assets, the declining equity and persistent liabilities pose financial stability concerns.

Cash Flow

The company has consistently experienced negative operating and free cash flows, indicating cash outflows in core operations and lack of free cash generation. Despite financing inflows, the inability to generate positive cash flow from operations remains a critical challenge. The cash flow situation suggests financial strain and a need for improved cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	797.92K	509.59K	152.43K	969.78K	355.80K	483.05K
Gross Profit	797.92K	508.83K	-149.61K	683.37K	350.71K	464.33K
EBITDA	-4.02M	-4.34M	-6.33M	-15.20M	-10.97M	-10.37M
Net Income	-4.12M	-4.90M	-7.79M	-16.42M	-12.84M	-9.79M
Balance Sheet
Total Assets	21.18M	7.54M	7.78M	10.93M	13.70M	14.77M
Cash, Cash Equivalents and Short-Term Investments	257.24K	928.55K	796.09K	1.47M	5.94M	5.00M
Total Debt	1.39M	3.20M	2.77M	3.41M	3.34M	6.77M
Total Liabilities	6.68M	6.82M	6.53M	6.34M	4.83M	8.94M
Stockholders Equity	12.06M	1.23M	1.55M	4.45M	8.84M	6.60M
Cash Flow
Free Cash Flow	-2.06M	-1.81M	-4.21M	-7.52M	-7.62M	-4.56M
Operating Cash Flow	-2.06M	-1.81M	-4.19M	-7.40M	-7.60M	-4.56M
Investing Cash Flow	-1.94M	0.00	-360.19K	-1.72M	-805.97K	-225.43K
Financing Cash Flow	4.07M	1.98M	3.87M	4.01M	10.00M	9.57M

ABVC BioPharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.43
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABVC, the sentiment is Negative. The current price of 2.43 is above the 20-day moving average (MA) of 2.20, below the 50-day MA of 2.49, and above the 200-day MA of 2.35, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 40.03 is Neutral, neither overbought nor oversold. The STOCH value of 30.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABVC.

ABVC BioPharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAMP	58 Neutral	$307.66M	-2.46	-172.70%	―	―	5.51%
HYFT	54 Neutral	$127.00M	-4.42	-121.76%	―	-17.94%	21.43%
JSPR	52 Neutral	$42.26M	-0.25	-191.12%	―	―	-24.38%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CRVO	49 Neutral	$71.57M	-2.62	-71.42%	―	-38.81%	-76.96%
INKT	48 Neutral	$58.21M	-3.95	―	―	―	21.48%
ABVC	44 Neutral	$52.98M	-9.32	-40.32%	―	56.52%	75.22%